Evidence map›Paper›PMID 35889155›Full record

ArticleMicroorganisms2022

How a PCR Sequencing Strategy Can Bring New Data to Improve the Diagnosis of Ethionamide Resistance.

Thomas Maitre, Florence Morel, Florence Brossier, Wladimir Sougakoff, Jéremy Jaffre, Sokleaph Cheng, Nicolas Veziris, Alexandra Aubry, On Behalf Of The Nrc-MyRMA

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Effects of mutations in multiple Ethionamide-resistance-associated genes amongFrontiers in cellular and infection microbiology · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Thomas MaitreCentre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, AP-HP (Assistance Publique Hôpitaux de Paris), Sorbonne-Université, F-75013 Paris, France.
Florence MorelCentre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, AP-HP (Assistance Publique Hôpitaux de Paris), Sorbonne-Université, F-75013 Paris, France.ORCID 0000-0003-0848-1198
Florence BrossierCentre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, AP-HP (Assistance Publique Hôpitaux de Paris), Sorbonne-Université, F-75013 Paris, France.
Wladimir SougakoffCentre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, AP-HP (Assistance Publique Hôpitaux de Paris), Sorbonne-Université, F-75013 Paris, France.
Jéremy JaffreCentre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, AP-HP (Assistance Publique Hôpitaux de Paris), Sorbonne-Université, F-75013 Paris, France.
Sokleaph ChengCentre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, AP-HP (Assistance Publique Hôpitaux de Paris), Sorbonne-Université, F-75013 Paris, France.
Nicolas VezirisCentre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, AP-HP (Assistance Publique Hôpitaux de Paris), Sorbonne-Université, F-75013 Paris, France.
Alexandra AubryCentre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, AP-HP (Assistance Publique Hôpitaux de Paris), Sorbonne-Université, F-75013 Paris, France.ORCID 0000-0003-4230-4793
On Behalf Of The Nrc-MyRMA
Inserm · FRSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ethionamide (ETH) is a second-line antituberculosis drug. ETH resistance (ETH-R) is mainly related to the mutations of the monooxygenase-activating ETH (EthA), the ETH target (InhA), and the

Indexed as

ethionamidemolecular diagnosisresistancetuberculosis

Identifiers

PMID35889155
PMCPMC9316172
OpenAlexW4285733020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.